JP2017519006A5 - - Google Patents

Download PDF

Info

Publication number
JP2017519006A5
JP2017519006A5 JP2016572543A JP2016572543A JP2017519006A5 JP 2017519006 A5 JP2017519006 A5 JP 2017519006A5 JP 2016572543 A JP2016572543 A JP 2016572543A JP 2016572543 A JP2016572543 A JP 2016572543A JP 2017519006 A5 JP2017519006 A5 JP 2017519006A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
small molecule
naltrexone
inhibitor
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016572543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017519006A (ja
JP6620338B2 (ja
Filing date
Publication date
Priority claimed from GBGB1410216.4A external-priority patent/GB201410216D0/en
Application filed filed Critical
Publication of JP2017519006A publication Critical patent/JP2017519006A/ja
Publication of JP2017519006A5 publication Critical patent/JP2017519006A5/ja
Application granted granted Critical
Publication of JP6620338B2 publication Critical patent/JP6620338B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016572543A 2014-06-09 2015-06-09 低用量ナルトレキソンによるがん細胞の準備刺激 Active JP6620338B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1410216.4A GB201410216D0 (en) 2014-06-09 2014-06-09 Therapeutic
GB1410216.4 2014-06-09
PCT/GB2015/051686 WO2015189597A1 (en) 2014-06-09 2015-06-09 Priming of cancer cells with low dose naltrexone

Publications (3)

Publication Number Publication Date
JP2017519006A JP2017519006A (ja) 2017-07-13
JP2017519006A5 true JP2017519006A5 (enExample) 2018-07-05
JP6620338B2 JP6620338B2 (ja) 2019-12-18

Family

ID=51266919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016572543A Active JP6620338B2 (ja) 2014-06-09 2015-06-09 低用量ナルトレキソンによるがん細胞の準備刺激

Country Status (10)

Country Link
US (3) US11065245B2 (enExample)
EP (1) EP3151831B1 (enExample)
JP (1) JP6620338B2 (enExample)
DK (1) DK3151831T3 (enExample)
ES (1) ES2730348T3 (enExample)
GB (1) GB201410216D0 (enExample)
PL (1) PL3151831T3 (enExample)
PT (1) PT3151831T (enExample)
TR (1) TR201908660T4 (enExample)
WO (1) WO2015189597A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response
GB201704913D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd Method
GB201704911D0 (en) * 2017-03-28 2017-05-10 Ldn Pharma Ltd High dose combo I
GB201704909D0 (en) 2017-03-28 2017-05-10 Ldn Pharma Ltd Cancer therapy
EP3482751A1 (en) 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
EP3934647A1 (en) * 2019-03-06 2022-01-12 LDN Pharma Limited Method for determining efficacy
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment
CN114364402A (zh) 2019-07-15 2022-04-15 罗瓦萨公司 用于治疗癌症的阿片类生长因子受体(ogfr)拮抗剂，特别是纳洛酮和/或纳曲酮

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
JP2015107918A (ja) 2012-02-14 2015-06-11 国立研究開発法人国立がん研究センター 抗がん剤の作用を増強する医薬組成物、がん治療用キット、診断薬、及びスクリーニング方法
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic

Similar Documents

Publication Publication Date Title
JP2017519006A5 (enExample)
US11220477B2 (en) Modulators of the eIF2alpha pathway
BR112017024777A2 (pt) uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados?
KR20160006668A (ko) 브루톤 티로신 키나제 억제제와 cyp3a4 억제제의 배합물
JP2014528423A5 (enExample)
KR20170042614A (ko) Btk 저해제를 이용한 치료에 대한 dlbcl의 반응을 예측하기 위한 바이오마커
BR112018002046A2 (pt) métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
WO2020163598A1 (en) Immunophilin-dependent inhibitors and uses thereof
WO2019090272A1 (en) Chemokine receptor modulators for treatment of epstein barr virus positive cancer
JP2017513908A5 (enExample)
EA201500373A1 (ru) Маситиниб или его соль для лечения рака, фармацевтическая композиция, лекарственное средство и набор
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
EA201171415A1 (ru) Ингибиторы белков семейства iap
RU2016136504A (ru) ПРИМЕНЕНИЕ ЭРИБУЛИНА И ИНГИБИТОРОВ mTOR В КАЧЕСТВЕ КОМБИНИРОВАННОЙ ТЕРАПИИ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ
JP2019506392A5 (enExample)
MX2022011372A (es) Composiciones de zinc-y-pga y metodos para tratar el cancer.
WO2018148598A1 (en) Compositions for treating breast cancer
Chen et al. The antipancreatic cancer activity of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2
EP3411058B1 (en) Combination therapy with a6 and paclitaxel for the treatment of ovarian cancer
BR112019008698A2 (pt) método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica
BRPI0715609A2 (pt) Composto, uso de um composto, métodos para produzir um efeito antiproliferativo em um animal de sangue quente, e para tratar uma doença em um animal de sangue quente, e, composição farmacêutica
Ma et al. Unraveling the triad of immunotherapy, tumor microenvironment, and skeletal muscle biomechanics in oncology
WO2020146779A1 (en) mTORC1 INHIBITORS FOR ACTIVATING AUTOPHAGY
JP2010510495A5 (enExample)
CA3093568A1 (en) Combination treatment of chemoresistant cancers